Ipca Laboratories Ltd
NSE: IPCALAB BSE: 524494
₹1533.90
(2.86%)
Thu, 12 Mar 2026, 10:48 pm
Market Cap378.03B
PE Ratio42.77
Dividend0.27
Health Technology
Pharmaceuticals: Major
24.5KIpca Laboratories Analysis
dividend
- Ipca Laboratories is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
- No need to calculate the sustainability of Ipca Laboratories's dividends as it is not paying a notable one for India.
- No need to calculate the sustainability of Ipca Laboratories's dividends in 3 years as they are not expected to pay a notable one for India.
- Ipca Laboratories is not paying a notable dividend for India, therefore no need to check if the payments are stable.
- Ipca Laboratories's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Ipca Laboratories's dividend is below the markets top 25% of dividend payers in India (3.08%).
future
- Ipca Laboratories's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- Ipca Laboratories's earnings are expected to exceed the low risk growth rate next year.
- Performance (ROE) is expected to be above the current IN Pharmaceuticals industry average.
- An improvement in Ipca Laboratories's performance (ROE) is expected over the next 3 years.
- Ipca Laboratories's revenue growth is expected to exceed the India market average.
- Cash flow for Ipca Laboratories is expected to increase but not above the 50% threshold in 2 years time.
- Ipca Laboratories's earnings are expected to grow by 18.4% yearly, however this is not considered high growth (20% yearly).
- Ipca Laboratories's earnings growth is positive but not above the India market average.
- Ipca Laboratories's net income is expected to increase but not above the 50% threshold in 2 years time.
- Ipca Laboratories is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
- Ipca Laboratories's revenue is expected to increase but not above the 50% threshold in 2 years time.
- Ipca Laboratories's revenue is expected to grow by 12.9% yearly, however this is not considered high growth (20% yearly).
health
- Ipca Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Ipca Laboratories is profitable, therefore cash runway is not a concern.
- Ipca Laboratories is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (425.2%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 21.9x debt.
- Ipca Laboratories's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (39.8% vs 3.6% today).
- Ipca Laboratories earns more interest than it pays, coverage of interest payments is not a concern.
- Ipca Laboratories's level of debt (3.6%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Ipca Laboratories board of directors is about average.
- Premchand's compensation has been consistent with company performance over the past year, both up more than 20%.
- Premchand's remuneration is higher than average for companies of similar size in India.
past
- Ipca Laboratories's 1-year earnings growth exceeds its 5-year average (57% vs 25.9%)
- Ipca Laboratories has delivered over 20% year on year earnings growth in the past 5 years.
- Ipca Laboratories used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Ipca Laboratories has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Ipca Laboratories's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (57% vs 22.7%).
- Ipca Laboratories has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- IPCALAB outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- IPCALAB outperformed the Market in India which returned -14.5% over the past year.
- Ipca Laboratories's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Ipca Laboratories's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Ipca Laboratories is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Ipca Laboratories is poor value based on expected growth next year.
- Ipca Laboratories is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Ipca Laboratories is overvalued based on earnings compared to the India market.
- NSEI:IPCALAB is flat (0.2%) underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- NSEI:IPCALAB is flat (0.2%) underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800